ACTRN12605000777695尚未招募3 期
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145mg fenofibrate and simvastatin with 40mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone
Fournier Laboratories Ireland0 个研究点目标入组 400 人开始时间: 2005年12月7日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Patients with mixed dyslipidemia with CHD or CHD risk equivalent or with multiple risk factor and a 10 year risk above or equal to 10% and with TG above 1.71mmol/l and LDL >2.58 or >3.36mmol/l according to risk after 6 weeks of treatment with 40mg simvastatin.
排除标准
- •Diabetes, CK>2 times ULN, creatinine clearance > 80ml/min, LFTs >2 times ULN.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapyType II DiabetesEUCTR2008-001246-21-PLovartis Pharma Services AG300
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.EUCTR2006-005851-14-LVFOURNIER LABORATORIES IRELAND Ltd1,500
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.Study in patients with mixed dyslipidemia (type IIb) at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.MedDRA version: 9.1Level: LLTClassification code 10027763Term: Mixed hyperlipidemiaEUCTR2006-005851-14-LTFOURNIER LABORATORIES IRELAND Ltd1,945
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.Study in patients with mixed dyslipidemia (type IIb) at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.MedDRA version: 9.1Level: LLTClassification code 10027763Term: Mixed hyperlipidemiaEUCTR2006-005851-14-EEFOURNIER LABORATORIES IRELAND Ltd1,945
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapyType II DiabetesEUCTR2008-001246-21-FRovartis Pharma Services AG300